Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42336   clinical trials with a EudraCT protocol, of which   6971   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Allopurinol in the prevention of superficial bladder tumour recurrence

    Summary
    EudraCT number
    2005-003219-66
    Trial protocol
    GB  
    Global end of trial date
    06 Jan 2015

    Results information
    Results version number
    v1(current)
    This version publication date
    26 Feb 2020
    First version publication date
    26 Feb 2020
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    EDGE ID 34160
    Additional study identifiers
    ISRCTN number
    ISRCTN65811336
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    University Hospitals of Leicester NHS Trust
    Sponsor organisation address
    Infirmary Square, Leicester, United Kingdom, LE1 5WW
    Public contact
    Mr L Griffiths, University Hospitals of Leicester NHS Trust, trlg1@le.ac.uk
    Scientific contact
    Mr L Griffiths, University Hospitals of Leicester NHS Trust, trlg1@le.ac.uk
    Sponsor organisation name
    University Hospitals of Leicester NHS Trust
    Sponsor organisation address
    Infirmary Square. Infirmary Road, Leicester, United Kingdom, LE1 5WW
    Public contact
    Mr Griffiths, University Hospitals of Leicester NHS Trust, trlg1@le.ac.uk
    Scientific contact
    Mr Griffiths, University Hospitals of Leicester NHS Trust, trlg1@le.ac.uk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    06 Jan 2015
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    06 Jan 2015
    Global end of trial reached?
    Yes
    Global end of trial date
    06 Jan 2015
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    Patients with superficial bladder cancer, at intermediate and high risk of recurrence could benefit from an oral medication(allopurinol) used in a cancer prevention role, and thereby reduce the need for repeated hospital admissions for surgery to remove the bladder tumour (TURBT) and invasive check-up procedures(Cystoscopy). This would not only have financial benefits to the health service but also reduce patient anxiety.
    Protection of trial subjects
    Ethics favourable opinion will be obtained from an appropriate committee. The Trust R&D approval is mandatory
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    08 Sep 2006
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 24
    Worldwide total number of subjects
    24
    EEA total number of subjects
    24
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    17
    85 years and over
    7

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The aim is to recruit 64 patients 32 to receive allopurinol and 32 to receive placebo Randomisation procedure The pharmacy department at Leicester General Hospital will randomise patients once allocated to Group A, B or C.

    Pre-assignment
    Screening details
    First superficial TCC bladder cancer diagnosis within 12 months Patients with solitary TCC Ta or T1 bladder tumour (Grade 1 or 2) that recurs at 3 months OR Patients with multifocal TCC Ta bladder tumours (Grade 1 or 2) that do not recur at 3 months OR Patients with multifocal TCC Ta bladder tumours (Grade 1 or 2) that recur at 3 months.

    Pre-assignment period milestones
    Number of subjects started
    24
    Number of subjects completed
    24

    Period 1
    Period 1 title
    Randomisation (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    ARM 1
    Arm description
    Allopurinol
    Arm type
    Experimental

    Investigational medicinal product name
    Allopurinol (Zyloric)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    100mg tablet by oral administration daily

    Arm title
    Arm 2
    Arm description
    Placebo
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo - Lactose
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    One tablet daily

    Number of subjects in period 1
    ARM 1 Arm 2
    Started
    12
    12
    Completed
    12
    12

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Randomisation
    Reporting group description
    -

    Reporting group values
    Randomisation Total
    Number of subjects
    24 24
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    0 0
        From 65-84 years
    17 17
        85 years and over
    7 7
    Gender categorical
    Units: Subjects
        Female
    7 7
        Male
    17 17
    Subject analysis sets

    Subject analysis set title
    Recruitment
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Subjects consented that were randomised to the study

    Subject analysis sets values
    Recruitment
    Number of subjects
    24
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    0
        From 65-84 years
    17
        85 years and over
    7
    Age continuous
    Units:
        
    ±
    Gender categorical
    Units: Subjects
        Female
    7
        Male
    17

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    ARM 1
    Reporting group description
    Allopurinol

    Reporting group title
    Arm 2
    Reporting group description
    Placebo

    Subject analysis set title
    Recruitment
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Subjects consented that were randomised to the study

    Primary: Time to biopsy proven recurrence

    Close Top of page
    End point title
    Time to biopsy proven recurrence [1]
    End point description
    End point type
    Primary
    End point timeframe
    12 months
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis was undertaken for this study due to insufficient recruitment
    End point values
    ARM 1 Arm 2
    Number of subjects analysed
    0 [2]
    0 [3]
    Units: Days
        number (not applicable)
    Notes
    [2] - Insufficient numbers for analysis
    [3] - insufficient numbers for analysis
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information [1]
    Timeframe for reporting adverse events
    12 months
    Adverse event reporting additional description
    Adverse events were not collected for this study
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    22.1
    Reporting groups
    Reporting group title
    ARM 1
    Reporting group description
    Experimental

    Reporting group title
    ARM 2
    Reporting group description
    -

    Notes
    [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
    Justification: non serious adverse events were not collected for this study
    Serious adverse events
    ARM 1 ARM 2
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 12 (25.00%)
    1 / 12 (8.33%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Injury, poisoning and procedural complications
    Post procedural haematuria
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 12 (8.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Surgical and medical procedures
    Transurethral prostatectomy
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 12 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Inferior ST elevated myocardia infarct Inferior STEMI
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 12 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Urinary retention
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 12 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Bilateral epididymo orchitis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 12 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    ARM 1 ARM 2
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 12 (0.00%)

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA